Nautilus Biotechnology, Inc. (NAUT)

US — Healthcare Sector
Peers: FHTX  IMRX  ENTA  PYXS  TNYA  ZURA  ASMB  HUMA  SGMT  ARCT 

Automate Your Wheel Strategy on NAUT

With Tiblio's Option Bot, you can configure your own wheel strategy including NAUT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NAUT
  • Rev/Share 0.0761
  • Book/Share 1.34
  • PB 1.679
  • Debt/Equity 0.1596
  • CurrentRatio 14.9549
  • ROIC -0.364

 

  • MktCap 284186525.0
  • FreeCF/Share -0.4272
  • PFCF -5.2708
  • PE -4.5212
  • Debt/Assets 0.1344
  • DivYield 0
  • ROE -0.3335

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade NAUT Goldman Neutral Sell -- $1.75 Dec. 5, 2024

News

Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
NAUT
Published: October 28, 2025 by: Seeking Alpha
Sentiment: Neutral

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Sujal Patel - Co-Founder, CEO, President, Secretary & Director Kentaro Suzuki - Chief Marketing Officer Anna Mowry - CFO & Treasurer Conference Call Participants Ji-Yon Yi William Ruby - TD Cowen, Research Division Presentation Operator Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Third Quarter 2025 Earnings Conference Call.

Read More
image for news Nautilus Biotechnology, Inc. (NAUT) Q3 2025 Earnings Call Transcript
Nautilus Biotechnology to Participate in Upcoming September Investor Conferences
NAUT
Published: August 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences.

Read More
image for news Nautilus Biotechnology to Participate in Upcoming September Investor Conferences

About Nautilus Biotechnology, Inc. (NAUT)

  • IPO Date 2020-08-07
  • Website https://www.nautilus.bio
  • Industry Biotechnology
  • CEO Sujal M. Patel
  • Employees 134
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.